Beckman Coulter, Inc.

Exclusive license agreement signed for intellectual property

Published in Drug Law Weekly, February 8th, 2005

Beckman Coulter, Inc., (BEC) and Critical Therapeutics, Inc., (CRTX) announced the signing of an exclusive license agreement under which Critical Therapeutics has granted Beckman Coulter certain rights in its patents, patent applications and other intellectual property relating to Critical Therapeutics' proprietary High Mobility Group Box Protein 1 (HMGB1) technology.

Beckman Coulter intends to use the HMGB1 technology to develop an immunoassay for detection and management of inflammatory diseases. In return, Critical Therapeutics will receive a license fee, as well as the potential for future development milestones and royalties contingent on sales of any diagnostic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2005-02-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry